Rein Therapeutics, Inc.
RNTXNext catalyst
LTI-03
Idiopathic Pulmonary Fibrosis (IPF)
Get an email about RNTX's next catalysts
Track Rein Therapeutics (RNTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
RNTX Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.10 | FQ end Sep/2026 | Call: tbd
LTI-03 Phase 2 Est. Readout
Primary completion for LTI-03 trial (NCT06968845) in Idiopathic Pulmonary Fibrosis (IPF)
SourceMarket Overview
Stock performance and key metrics
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Rein Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Rein Therapeutics, Inc.'s (RNTX) pipeline across Phase 2. Its lead program is LTI-03 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Rein Therapeutics, Inc.'s next FDA catalyst?→
Rein Therapeutics, Inc.'s (RNTX) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track RNTX biotech catalysts?→
Add RNTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Rein Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.